European Union: AG Mazák Advises ECJ To Dismiss AstraZeneca Appeal Against Finding Of Abuse Of Dominant Position – Mondaq

According to the Commission, AstraZeneca made misleading representations to national patent offices in order to obtain supplementary protection of its patent for the active ingredient (omeprazole) of its anti-ulcer medicine, Losec®. The Commission also …

Leave a Reply

Your email address will not be published. Required fields are marked *